Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 92.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,773 shares of the company's stock after buying an additional 221,458 shares during the period. Price T Rowe Associates Inc. MD owned approximately 1.21% of Tarsus Pharmaceuticals worth $25,514,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $25,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $53,000. HighTower Advisors LLC purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $207,000. Summit Investment Advisors Inc. lifted its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $223,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Trading Down 1.6 %

Shares of Tarsus Pharmaceuticals stock traded down $0.77 on Tuesday, reaching $47.24. The company had a trading volume of 42,293 shares, compared to its average volume of 694,395. The firm's 50 day moving average price is $48.05 and its two-hundred day moving average price is $48.98. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The firm has a market cap of $1.98 billion, a PE ratio of -12.40 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the topic of several analyst reports. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday. Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Jefferies Financial Group raised their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $66.33.

Insider Activity at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now directly owns 58,057 shares of the company's stock, valued at $2,687,458.53. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 in the last three months. 8.25% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.